サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363011

カルバペネムの市場規模、シェア、動向分析レポート：薬剤クラス別、用途別、流通チャネル別、地域別、セグメント別予測、2023年～2030年

Carbapenem Market Size, Share & Trends Analysis Report By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (UTI, Blood Stream Infections, Pneumonia), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 236 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
カルバペネムの市場規模、シェア、動向分析レポート：薬剤クラス別、用途別、流通チャネル別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月13日
発行: Grand View Research
ページ情報: 英文 236 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

カルバペネム市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のカルバペネム市場規模は2030年までに52億4,000万米ドルに達し、2023年から2030年までのCAGRは4.78%に達すると予測されています。

カルバペネムの使用率の上昇、抗生物質の処方率の上昇、研究開発の進展による新薬の登場などが、予測期間中の市場成長を促進すると予想される要因のいくつかです。

2022年11月に発表された米国肺協会の論文によると、肺炎は一般に認識されている以上に蔓延しており、年間100万人以上の入院を引き起こし、5万人以上の死者を出しています。2023年5月、アンタビオ社は、院内感染に対する抗生物質療法の初回投与量を健康なボランティアに投与することで、第I相試験を開始しました。MEM-ANT3310として知られるこの治療法は、メロペネム（MEM）とアンタビオの新規広域セリンβ-ラクタマーゼ阻害剤ANT3310を組み合わせたものです。このことが、予測期間における市場の成長を後押ししています。

さらに、パンデミックの間、世界中の医療システムは、特にICU環境におけるCOVID-19の重症症例の管理で計り知れない課題に直面しました。重症のCOVID-19患者の多くは、二次的な細菌感染に対処するための抗生物質の使用を含む高度な医療を必要としていました。強力な広域抗生物質であるカルバペネムは、これらの患者の細菌感染症に対する治療選択肢の1つでした。このように、COVID-19パンデミックの期間中、市場に大きな影響があっています。

北米、特に米国における医薬品規制の枠組みは確立されており、医薬品承認への明確な道筋を提供しています。例えば、2022年8月、ブルックス・ラボラトリーズは、その子会社であるブルックス・ステリサイエンスが、米国食品医薬品局（USFDA）から、1バイアル当たり500mgと1バイアル当たり1グラムの製品であるメロペネム注の承認を取得したと発表しました。この製品は、ファイザー社のメルレム注と同等のジェネリック医薬品です。

しかし、カルバペネムを含む抗生物質の過剰使用や誤用は、抗菌薬耐性（AMR）の発達に寄与しています。細菌が進化を続け、これらの薬剤に耐性を持つようになると、感染症治療における有効性が低下し、カルバペネムやその他の抗生物質にとって重大な課題となります。

カルバペネム市場レポートハイライト

  • 薬剤クラス別では、多剤耐性株を含むさまざまな細菌に対する広域スペクトル活性により、メロペネムセグメントが2022年の市場を独占しました。その他のセグメントは最も速いCAGRで成長すると予測されます。
  • 用途別では、尿路感染症（UTI）分野が2022年に市場で最大のシェアを占め、最も速い成長率が予想されます。尿路感染症は、世界中で最も一般的な細菌感染症であると考えられています。
  • 流通チャネル別では、病院薬局セグメントが2022年に市場を独占し、細菌感染症の有病率の上昇により、最も速いCAGR率で成長すると予測されています。
  • 2022年には、大手市場プレイヤーの存在と強固な医療インフラにより、北米が市場を独占しました。これらにより、同地域のカルバペネム市場は予測期間中に拡大すると予測されます。
  • アジア太平洋地域は、尿路結石の高い有病率、医療支出の増加、インドや中国のような発展途上国における医療インフラの整備により、予測期間中に最も速い成長率で成長すると予測されます。

目次

第1章 カルバペネム市場：調査手法と範囲

第2章 カルバペネム市場：エグゼクティブサマリー

  • 市場スナップショット
  • 製品タイプと用途のスナップショット
  • 流通チャネルのスナップショット
  • 競合情勢のスナップショット

第3章 カルバペネム市場の変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因分析
    • 抗生物質耐性感染症の蔓延
    • 臨床研究への多額の研究開発投資
  • 市場抑制要因分析
    • カルバペネムの製造コストが高い
    • 副作用と安全性への懸念
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 カルバペネム市場：薬剤クラスの推定・動向分析

  • カルバペネム市場：薬剤クラスの変動分析
  • メロペネム
  • イミペネム
  • エルタペネム
  • その他

第5章 カルバペネム市場：用途の推定・動向分析

  • カルバペネム市場：用途の変動分析
  • 尿路感染症
  • 血流感染症
  • 腹腔内感染症
  • 肺炎
  • その他

第6章 カルバペネム市場：流通チャネルの推定・動向分析

  • カルバペネム市場：流通チャネルの変動分析
  • 病院薬局
  • 小売薬局
  • その他

第7章 カルバペネム市場：地域のビジネス分析

  • 地域の市場スナップショット
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 カルバペネム市場：競合情勢

  • 企業の分類
  • 戦略マッピング
  • 主要企業の市場シェア分析、2022年
  • 企業ヒートマップ分析
  • 企業プロファイル
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 1 List of abbreviation
  • Table 2 North America carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Europe carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Europe carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 UK carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 UK carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Germany carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 24 France carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Italy carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Italy carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Spain carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Spain carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Denmark carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Denmark carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Sweden carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Sweden carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Norway carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Norway carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 China carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 China carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 46 China carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Japan carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Japan carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 India carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 India carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 52 India carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Korea carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Korea carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Australia carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Australia carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Thailand carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 63 Latin America carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Latin America carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Brazil carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 Brazil carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Mexico carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 70 Mexico carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Argentina carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Middle East & Africa carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 76 Middle East & Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Middle East & Africa carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 78 Middle East & Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 80 South Africa carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 UAE carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Kuwait carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait carbapenem market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global carbapenem market - Key market driver analysis
  • Fig. 7 Global carbapenem market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global carbapenem market - Porter's analysis
  • Fig. 10 Global carbapenem market - PESTEL analysis
  • Fig. 11 Global carbapenem market drug class outlook key takeaways
  • Fig. 12 Global carbapenem market: Drug class movement analysis
  • Fig. 13 Meropenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 14 Imipenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 15 Ertapenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 16 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 17 Global carbapenem market application outlook key takeaways
  • Fig. 18 Global carbapenem market: application movement analysis
  • Fig. 19 Urinary tract infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 20 Bloodstream infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 21 Pneumonia market estimates, 2018 - 2030 (USD Million)
  • Fig. 22 Intra - abdominal infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 24 Global carbapenem market distribution channel outlook key takeaways
  • Fig. 25 Global carbapenem market: Test type movement analysis
  • Fig. 26 Hospital pharmacies market estimates, 2018 - 2030 (USD Million)
  • Fig. 27 Retail pharmacies market estimates, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Global carbapenem market: Regional movement analysis
  • Fig. 31 North America carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 35 UK carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 37 France carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 40 Denmark carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 42 Norway carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 45 China carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 46 India carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 54 MEA carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 59 Strategy framework
目次
Product Code: GVR-4-68040-118-4

Carbapenem Market Growth & Trends:

The global carbapenem market size is expected to reach USD 5.24 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 4.78% from 2023 to 2030. The rise in the utilization of carbapenem-based antibiotics, elevated prescription rates of antibiotics, and progress in research and development resulting in the upcoming novel medications; are a few of the factors that are anticipated to propel the growth of the market over the forecast period.

According to an American Lung Association article, published in November 2022, Pneumonia is more prevalent than commonly perceived, leading to over a million hospitalizations and causing more than 50,000 deaths annually. In May 2023, Antabio initiated its Phase I trial by administering the initial dose of antibiotic therapy to healthy volunteers for hospital-acquired infections. The therapy, known as MEM-ANT3310, combines meropenem (MEM) with Antabio's novel broad-spectrum serine beta-lactamase inhibitor, ANT3310. This is fueling the growth of the market over the forecast period.

Moreover, during the pandemic, healthcare systems worldwide faced immense challenges in managing severe cases of COVID-19, especially in ICU settings. Many critically ill COVID-19 patients required advanced medical care, including the use of antibiotics to address secondary bacterial infections. Carbapenems, being potent broad-spectrum antibiotics, were one of the treatment options considered for bacterial co-infections in these patients. Thus, there was a significant impact during the period of the COVID-19 pandemic on the market.

The regulatory framework for pharmaceuticals in North America, particularly in the United States, is well-established and provides a clear pathway for drug approvals. For instance, in August 2022, Brooks Laboratories made an announcement stating that its subsidiary, Brooks Steriscience, has obtained approval from the United States Food & Drug Administration (USFDA) for the product, Meropenem Injection, available in 500mg per vial and 1gram per vial. This product serves as the generic equivalent to Pfizer Inc.'s Merrem Injection.

However, the overuse and misuse of antibiotics, including carbapenems, contribute to the development of antimicrobial resistance (AMR). As bacteria continue to evolve and become resistant to these drugs, their effectiveness in treating infections diminishes, posing a significant challenge for carbapenems and other antibiotics.

Carbapenem Market Report Highlights:

  • Based on drug class, the meropenem segment dominated the market in 2022, owing to their broad-spectrum activity against various bacteria, including multidrug-resistant strains. Other segment is anticipated to grow at the fastest CAGR rate
  • Based on application, the urinary tract infections (UTIs) segment held the largest share of the market in 2022 and is anticipated to grow at the fastest growth rate. UTIs are considered to be the most common bacterial infections across the globe
  • Based on the distribution channel, the hospital pharmacies segment dominated the market in 2022 and is anticipated to grow at the fastest CAGR rate owing to the rising prevalence of bacterial infections
  • In 2022, North America dominated the market, owing to the presence of major market players, and robust healthcare infrastructure. These are anticipated to boost the market for carbapenem in the region over the forecast period
  • Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to the high prevalence of UTIs, growing healthcare spending, and the development of healthcare infrastructure in developing countries like India and China

Table of Contents

Chapter 1. Carbapenem Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Type Segment
      • 1.1.1.2. Drug Class Segment
      • 1.1.1.3. Application Segment
      • 1.1.1.4. Distribution Channel Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Carbapenem Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product Type and Application Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Carbapenem Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing prevalence of antibiotic-resistant infections
    • 3.4.2. High R&D investments in clinical research
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of production of carbapenem-based antibiotics
    • 3.5.2. Side effects and safety concerns
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Carbapenem Market: Drug Class Estimates & Trend Analysis

  • 4.1. Carbapenem Market: Drug Class Movement Analysis
  • 4.2. Meropenem
    • 4.2.1. Meropenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Imipenem
    • 4.3.1. Imipenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ertapenem
    • 4.4.1. Ertapenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Carbapenem Market: Application Estimates & Trend Analysis

  • 5.1. Carbapenem Market: Application Movement Analysis
  • 5.2. Urinary Tract Infections
    • 5.2.1. Urinary Tract Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Bloodstream Infections
    • 5.3.1. Bloodstream Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Intra-abdominal Infections
    • 5.4.1. Intra-abdominal Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Pneumonia
    • 5.5.1. Pneumonia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Carbapenem Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Carbapenem Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Carbapenem Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Carbapenem Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.4.2. Key Country Dynamics
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Carbapenem Market: Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Type Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaborotion
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2022
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. The Menarini Group
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sun Pharmaceutical Industries Ltd
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Lupin
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Kopran Limited
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Aurobindo Pharma
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Daewoong Pharmaceuticals Co., Ltd.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Product Benchmarking
      • 8.5.7.3. Strategic Initiatives
    • 8.5.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Product Benchmarking
      • 8.5.8.3. Strategic Initiatives
    • 8.5.9. Merck & Co., Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Venus Remedies Ltd
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives